Strategic partnerships Lead program in inflammatory bowel disease nearing clinic with validated partnerships from Biohaven Pharmaceuticals, Brii Biosciences, and the Crohn’s & Colitis Foundation, signaling potential for co-development, sponsored trials, and early-access opportunities.

Microbiome focus Specializes in microbiome precision medicine leveraging IgA-SEQ and microbial virulence factor targeting, presenting a sales angle to CROs and pharma looking to collaborate on microbiome-driven inflammation therapies or companion diagnostics.

Financing momentum Recent Series A-2 funding and ongoing investor interest indicate strong capital availability for partnered research, enabling joint ventures, milestone-based collaborations, and funded research programs.

Clinical progression Lead candidate ARZC-001 for IBD positions Artizan to engage late-stage clinical development partners, contract research organizations, and specialty pharma seeking novel intestinal inflammation therapeutics.

New Haven footprint Located in New Haven, CT with academic ties to Yale-origin immunobiology and recent collaboration with international centers, offering opportunities to connect with regional biotech networks, grant collaborations, and talent sourcing.